



## Technology Advisory Committee B Interests Register Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]

Publication Date: 19/10/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Nick Latimer	Committee Member	Non-financial professional and personal	I am a member of the ScHARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme. This is not drug or appraisal specific and is about developing methods. Merck, Sharpe and Dohme are the manufacturer.		12/05/22 13/07/22		It was agreed that this declaration would not prevent Professor Latimer from taking part in this discussion
Ms Sophie-Ann Scott	Patient expert	Indirect financial	My organisation - Kidney cancer UK - has received funding from Pfizer Merck and BMS for various projects.	14/09/21	12/05/22 13/07/22		It was agreed that this declaration would not prevent Sophie-Ann Scott from providing expert advice during this discussion.
Dr Natalie Charnley	Clinical expert	Direct financial	I have received meeting sponsorship from BMS, Ipsen and Eusa, and speaker fees from Pfizer and Ipsen and I	27/04/22	12/05/22 13/07/22		It was agreed that these declarations would not prevent Dr Charnley from providing expert advice in this discussion



			have received research sponsorship from BMS.			
		Indirect financial interest	(Kidney Cancer UK) has received funding from BMS, Merck and Pfizer.			
Professor Thomas Powles	Clinical expert	Direct financial interest	I have received renumeration by MSD for my work on advisory boards	12/05/22	12/05/22 13/07/22	It was agreed that these declarations would not prevent Professor Powles from providing expert advice during this
			I have sat on	27/09/21		discussion.
		Indirect financial	advisory/research boards			
		interest	(honorarium) for the following			
			pharmaceutical companies:			
			AstraZeneca, BMS, Exelixis,			
			Incyte, Ipsen, Merck,			
			Novartis, Pfizer, Seattle			
			Genetics, Merck Serono,			
			Astellas, Johnson & Johnson,			
			Eisai, and Roche. I received			
			travel/accommodation			
			expenses from the following			
			pharmaceutical companies: Roche, Pfizer, MSD,			
			AstraZeneca, Ipsen, and my			
			institution has received			
			grants/funding from			
			AstraZeneca, Roche, BMS,			
			Exelixis, Ipsen, Merck, MSD,			



Direct non- financial interest	Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai.  I have received academic credit for satellite symposia, co-leading the pembrolizumab study and leading on a number of trials for MSD.	12/05/22				
-----------------------------------	--	----------	--	--	--	--